Login
Subscribe
PLOS ONE Pulls Five Papers Tied to Alzheimer’s Drug Controversy
PLOS ONE Pulls Five Papers Tied to Alzheimer’s Drug Controversy
The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.
The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.
biotech, FDA, drug development
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019 | 2 min read
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
The Sounds of Silence
Jenny Rood | Sep 1, 2015 | 8 min read
Science-based tinnitus therapeutics are finally coming into their own.
FDA Approves 3-D–Printed Drug
Jef Akst | Aug 4, 2015 | 1 min read
The US Food and Drug Administration green lights the first medicine produced by a 3-D printer for use in the human body.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.